| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,¶
* Unit Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 601, Nantes, France;
Faculté des Sciences de Nantes, Nantes, France;
Antiviral Immunity, Biotherapy and Vaccine Unit, INSERM Unité 668, Institut Pasteur, Paris, France;
Unit of Cellular and Gene Therapy, Centre Hospitalier Régional Universitaire de Nantes, Nantes, France;
¶ Unit of Skin Cancer, Centre Hospitalier Régional Hotel Dieu, Nantes, France; and
|| Recombinant Protein Facility, Institut Féderatif de Recherche 26, Nantes, France
In this study, we report the adoptive transfer of highly tumor-reactive Melan-A-specific T cell clones to patients with metastatic melanoma, and the follow-up of these injected cells. These clones were generated from HLA-A*0201 patients by in vitro stimulations of total PBMC with the HLA-A*0201-binding Melan-A peptide analog ELAGIGILTV. Ten stage IV melanoma patients were treated by infusion of these CTL clones with IL-2 and IFN-
. The generated T cell clones, of effector/memory phenotype were selected on the basis of their ability to produce IL-2 in response to HLA-A*0201 Melan-A-positive melanoma lines. Infused clones were detected, by quantitative PCR, in the blood of three patients for periods ranging from 7 to 60 days. Six patients showed regression of individual metastases or disease stabilization, and one patient experienced a complete response, but no correlation was found between the detection of the infused clones in PBMC or tumor samples and clinical responses. Nonetheless, frequencies of Melan-A/A2-specific lymphocytes, measured by tetramer labeling, increased after treatment in most patients. In one of these patients, who showed a complete response, this increase corresponded to the expansion of new clonotypes of higher avidity than those detected before treatment. Together, our results suggest that infused CTL clones may have initiated an antitumor response that may have resulted in the expansion of a Melan-A-specific CTL repertoire.
This article has been cited by other articles:
|
|
 |
|
  Y. Godet, A. Moreau-Aubry, Y. Guilloux, V. Vignard, A. Khammari, B. Dreno, F. Jotereau, and N. Labarriere MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency J. Exp. Med., October 27, 2008; 205(11): 2673 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hambach, M. Vermeij, A. Buser, Z. Aghai, T. van der Kwast, and E. Goulmy Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors Blood, September 1, 2008; 112(5): 1844 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response Cancer Res., June 15, 2008; 68(12): 4882 - 4892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Carrasco, A. Van Pel, B. Neyns, B. Lethe, F. Brasseur, N. Renkvist, P. van der Bruggen, N. van Baren, R. Paulus, K. Thielemans, et al. Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells J. Immunol., March 1, 2008; 180(5): 3585 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weishaupt, K. N. Munoz, E. Buzney, T. S. Kupper, and R. C. Fuhlbrigge T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma Clin. Cancer Res., May 1, 2007; 13(9): 2549 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lesimple, E.-M. Neidhard, V. Vignard, C. Lefeuvre, H. Adamski, N. Labarriere, A. Carsin, D. Monnier, B. Collet, G. Clapisson, et al. Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients Clin. Cancer Res., December 15, 2006; 12(24): 7380 - 7388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma J. Clin. Oncol., November 1, 2006; 24(31): 5060 - 5069. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
